Market Cap
US$12.4m
Last Updated
2019/12/05 00:43 UTC
Data Sources
Company Financials +
Executive Summary
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample.
Rewards
Risk Analysis
Shareholders have been substantially diluted in the past year
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 2 more risks
Snowflake Analysis
Adequate balance sheet with limited growth.
Similar Companies
Share Price & News
How has Biocept's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BIOC's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
11.7%
BIOC
0.7%
US Biotechs
-1.4%
US Market
1 Year Return
-47.6%
BIOC
12.9%
US Biotechs
14.5%
US Market
Return vs Industry: BIOC underperformed the US Biotechs industry which returned 12.9% over the past year.
Return vs Market: BIOC underperformed the US Market which returned 14.5% over the past year.
Shareholder returns
| BIOC | Industry | Market | |
|---|---|---|---|
| 7 Day | 11.7% | 0.7% | -1.4% |
| 30 Day | -16.1% | 10.0% | 1.3% |
| 90 Day | -32.9% | 16.4% | 4.6% |
| 1 Year | -47.6%-47.6% | 13.9%12.9% | 17.1%14.5% |
| 3 Year | -97.7%-97.7% | 29.6%25.5% | 45.1%35.7% |
| 5 Year | -99.8%-99.8% | 6.6%1.5% | 67.1%48.6% |
Price Volatility Vs. Market
How volatile is Biocept's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall St
Could Biocept, Inc.'s (NASDAQ:BIOC) Investor Composition Influence The Stock Price?1 month ago | Simply Wall St
Is Biocept, Inc.'s (NASDAQ:BIOC) CEO Overpaid Relative To Its Peers?3 months ago | Simply Wall St
One Thing To Remember About The Biocept, Inc. (NASDAQ:BIOC) Share PriceValuation
Is Biocept undervalued compared to its fair value and its price relative to the market?
1.75x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BIOC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BIOC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BIOC is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: BIOC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BIOC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BIOC is good value based on its PB Ratio (1.8x) compared to the US Biotechs industry average (3.1x).
Next Steps
Future Growth
How is Biocept forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
30.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIOC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BIOC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BIOC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BIOC's revenue (58% per year) is forecast to grow faster than the US market (7.4% per year).
High Growth Revenue: BIOC's revenue (58% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BIOC's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Biocept performed over the past 5 years?
-12.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BIOC is currently unprofitable.
Growing Profit Margin: BIOC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BIOC is unprofitable, and losses have increased over the past 5 years at a rate of -12.4% per year.
Accelerating Growth: Unable to compare BIOC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIOC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).
Return on Equity
High ROE: BIOC has a negative Return on Equity (-330.13%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Biocept's financial position?
Financial Position Analysis
Short Term Liabilities: BIOC's short term assets ($10.6M) exceed its short term liabilities ($5.8M).
Long Term Liabilities: BIOC's short term assets ($10.6M) exceed its long term liabilities ($1.0M).
Debt to Equity History and Analysis
Debt Level: BIOC's debt to equity ratio (1.7%) is considered satisfactory.
Reducing Debt: BIOC's debt to equity ratio has reduced from 147.2% to 1.7% over the past 5 years.
Balance Sheet
Inventory Level: BIOC has a high level of physical assets or inventory.
Debt Coverage by Assets: BIOC's debt is covered by short term assets (assets are 79.6x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BIOC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: BIOC has less than a year of cash runway if free cash flow continues to reduce at historical rates of -13.8% each year
Next Steps
Dividend
What is Biocept's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate BIOC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate BIOC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BIOC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BIOC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BIOC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Biocept's salary, the management and board of directors tenure and is there insider trading?
3.4yrs
Average management tenure
CEO
Mike Nall (56yo)
6.3yrs
Tenure
US$439,720
Compensation
Mr. Michael W. Nall, also known as Mike, has been the Chief Executive Officer and President at Biocept, Inc. since August 26, 2013. Mr. Nall has over 30 years of leadership experience in healthcare sales, ...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD439.72K) is about average for companies of similar size in the US market ($USD508.62K).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
Management Age and Tenure
3.4yrs
Average Tenure
61yo
Average Age
Experienced Management: BIOC's management team is considered experienced (3.4 years average tenure).
Board Age and Tenure
8.7yrs
Average Tenure
71yo
Average Age
Experienced Board: BIOC's board of directors are considered experienced (8.7 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 615.8%.
Management Team
Soon Kap Hahn
- Tenure: 22.9yrs
Mike Terry (64yo)
Senior Vice President of Corporate Development
- Tenure: 0yrs
Lyle Arnold (72yo)
Senior VP of R&D
- Tenure: 0yrs
- Compensation: US$287.43k
David Moskowitz
Vice President of Strategy & Corporate Communications
- Tenure: 3.2yrs
Michael Brown
General Counsel and Compliance & Privacy Officer
- Tenure: 2.2yrs
Tim Kennedy (61yo)
CFO, Senior VP of Operations & Corporate Secretary
- Tenure: 3.4yrs
- Compensation: US$359.04k
Pavel Tsinberg
Director of Technology Development
- Tenure: 2.3yrs
Mike Nall (56yo)
CEO, President & Director
- Tenure: 6.3yrs
- Compensation: US$439.72k
Veena Singh (44yo)
Senior Medical Director
- Tenure: 5yrs
- Compensation: US$115.22k
Cory Dunn
Vice President of Marketing
- Tenure: 1.1yrs
Board Members
M. Wilson (81yo)
Lead Independent Director
- Tenure: 0yrs
- Compensation: US$56.16k
Ivor Royston (73yo)
Independent Director
- Tenure: 9.9yrs
- Compensation: US$41.16k
David Hale (70yo)
Non-Executive Chairman of the Board
- Tenure: 8.8yrs
- Compensation: US$102.41k
Bruce Huebner (68yo)
Independent Director
- Tenure: 6.1yrs
- Compensation: US$47.66k
Lyle Arnold (72yo)
Senior VP of R&D
- Tenure: 0yrs
- Compensation: US$287.43k
Claire Reiss
Chairwoman Emeritus
- Tenure: 8.7yrs
Marsha Chandler (74yo)
Independent Director
- Tenure: 6.1yrs
- Compensation: US$39.91k
Fred Hirsch
Member of Clinical Advisory Board
- Tenure: 0yrs
Bruce Gerhardt (68yo)
Independent Director
- Tenure: 9.2yrs
- Compensation: US$38.66k
Mike Nall (56yo)
CEO, President & Director
- Tenure: 6.3yrs
- Compensation: US$439.72k
Company Information
Biocept, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Biocept, Inc.
- Ticker: BIOC
- Exchange: NasdaqCM
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$12.421m
- Shares outstanding: 23.02m
- Website: https://www.biocept.com
Number of Employees
Location
- Biocept, Inc.
- 5810 Nancy Ridge Drive
- San Diego
- California
- 92121
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| BIOC | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Feb 2014 |
| B002 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Feb 2014 |
Biography
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/05 00:43 |
| End of Day Share Price | 2019/12/04 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.